[Management of patients with type 2 diabetes at cardiovascular and renal risk : ESC versus ADA-EASD].

Glucagon-like peptide-1 receptor agonists and SGLT2 inhibitors are now preferred treatments for type 2 diabetes patients at cardiovascular risk.

• These medications provide cardiovascular and renal protection beyond their effects on blood sugar levels.
• Recent guidelines from the European Society of Cardiology and the ADA-EASD highlight their importance in managing cardiovascular risk.
• Discrepancies exist in the definitions of cardiovascular risk patients, particularly in primary prevention contexts.
• Metformin remains the first-choice treatment for many patients despite the emerging role of these newer medications.

AI simplified